Joining the fight against the Coronavirus, Alsachim, one of the world leaders in TDM standards organic synthesis, is supporting healthcare actors to respond to the urgency caused by the acceleration of clinical trials conducted to find a COVID-19 treatment. Using exclusive labeled molecules, the Alsatian company is the first to provide the internal standards necessary for the therapeutic monitoring of these drugs.

Monitoring new treatment against COVID-19 is critical

For several weeks now, many laboratories and hospitals around the world have been carrying out studies to find a solution against the spread of this deadly virus. Several drugs are on the test bench such as Hydroxychloroquine, Favipiravir or Remdesivir. Used alone or in combination with other drugs, these molecules demonstrate promising results today. Regarding this exceptional situation, the authorities must drastically reduce the time to develop a treatment, which generally takes several years. For this reason, it is essential to quickly set up dosage methods to determine the optimal doses of these experimental treatments, in order to ensure a minimum level of efficacy, to avoid overdosage which causes undesirable side effects and toxicity, but also to avoid accidents due to self-medication.

Alsachim provides internal standards to hospitals worldwide.

Alsachim, expert in the research and development of stable isotope labeled compounds, has synthesized the internal standards necessary for the assay of the drugs tested against COVID-19. The company has increased its research activities and its production capacities in order to supply these standards to hospitals in France, Europe and around the world in record time. « Our team of chemists has been tirelessly mobilized since the beginning of the spread of the virus. We are the first to supply our customers with reference standards and metabolites of Remdesivir, Hydroxychloroquine or Favipiravir. Our expertise has allowed us to exclusively develop internal labeled standards allowing more reliable results. Our chemists work in priority on these compounds to send them to hospitals so that their teams can develop clinical analysis methods. ».

Alsachim strongly supports all research teams in France, and also in Europe, which have already made remarkable progress in finding effective drugs and treating patients infected with Covid-19.

« For more than 15 years, we have been working in close collaboration with hospitals, pharmaceutical laboratories and research centers around the world to anticipate their needs. We support health actors to develop new drugs and new methods of pharmacological therapeutic monitoring against cancer, bacterial infections, but also obesity or cardiovascular diseases. The emergency is now Coronavirus. Today, we want again to support all of our partners. » certified Dr. Jean-François Hoeffler, President of Alsachim.

Download the press release

For more information, please contact us: communication@alsachim.com

Discover the list of the labeled and unlabeled internal standards